Maxrets Ventures Plc

OFEX:MAX Stock Report

Market Cap: UK£332.8k

Maxrets Ventures Valuation

Is MAX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MAX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MAX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MAX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MAX?

Key metric: As MAX is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for MAX. This is calculated by dividing MAX's market cap by their current book value.
What is MAX's PB Ratio?
PB Ratio17.5x
BookUK£19.00k
Market CapUK£332.83k

Price to Book Ratio vs Peers

How does MAX's PB Ratio compare to its peers?

The above table shows the PB ratio for MAX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.4x
NFX Nuformix
0.09xn/aUK£385.1k
N4P N4 Pharma
2.1xn/aUK£2.6m
KNB Kanabo Group
1.1xn/aUK£6.3m
IMM ImmuPharma
2.4xn/aUK£6.5m
MAX Maxrets Ventures
17.5xn/aUK£332.8k

Price-To-Book vs Peers: MAX is expensive based on its Price-To-Book Ratio (17.5x) compared to the peer average (1.4x).

Price to Book Ratio vs Industry

How does MAX's PB Ratio compare vs other companies in the GB Pharmaceuticals Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
EAH ECO Animal Health Group
0.5x34.2%US$55.97m
OCTP Oxford Cannabinoid Technologies Holdings
0.6x15.1%US$1.60m
NFX Nuformix
0.09xn/aUS$481.93k
No more companies available in this PB range
MAX 17.5xIndustry Avg. 2.4xNo. of Companies3PB03.67.210.814.418+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: MAX is expensive based on its Price-To-Book Ratio (17.5x) compared to the European Pharmaceuticals industry average (2.3x).

Price to Book Ratio vs Fair Ratio

What is MAX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MAX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio17.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate MAX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€62.90

7D

1.5%

1Y

14.6%

hVIVO

UK£149.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.22

7D

-16.2%

1Y

22.2%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$748.39

7D

-1.7%

1Y

-6.3%